Long-acting beta 2-adrenoceptor agonists: a new perspective in the treatment of asthma
CG Lofdahl, KF Chung - European Respiratory Journal, 1991 - Eur Respiratory Soc
New long-acting beta 2-adrenoceptor agonists, formoterol and salmeterol, may soon appear
in several European countries for treatment of asthma. This review examines currently …
in several European countries for treatment of asthma. This review examines currently …
Long-Acting β2-Agonists: Comparative Pharmacology and Clinical Outcomes
HJ van der Woude, R Aalbers - American Journal of Respiratory Medicine, 2002 - Springer
Salmeterol and formoterol are both long-acting β 2-adrenoceptor agonists (β 2-agonists).
They both provide excellent bronchodilating and bronchoprotective effects in patients with …
They both provide excellent bronchodilating and bronchoprotective effects in patients with …
Long-acting β2-adrenoceptor agonists: a smart choice for asthma?
BJ Lipworth - Trends in pharmacological sciences, 2007 - cell.com
An endogenous defect in β 2-adrenoceptors that results in impaired relaxation of airway
smooth muscle was originally proposed as a putative underlying cause of the asthmatic …
smooth muscle was originally proposed as a putative underlying cause of the asthmatic …
Different bronchodilating effect of salmeterol and formoterol in an adult asthmatic
CS Ulrik, A Kok-Jensen - European Respiratory Journal, 1994 - erj.ersjournals.com
New long-acting beta 2-adrenoceptor agonists, salmeterol and formoterol, have recently
been marketed for treatment of asthma, but studies comparing the clinical efficacy of the two …
been marketed for treatment of asthma, but studies comparing the clinical efficacy of the two …
Inhaled beta 2‐adrenoceptor agonists in asthma: help or hindrance?
BJ Lipworth, DG McDevitt - British journal of clinical …, 1992 - Wiley Online Library
Conventional low doses of inhaled beta 2‐adrenoceptor agonists produce effective
bronchodilation without systemic effects. Higher doses of inhaled beta 2‐adrenoceptor …
bronchodilation without systemic effects. Higher doses of inhaled beta 2‐adrenoceptor …
Comparison of the effects of salmeterol and formoterol on airway tone and responsiveness over 24 hours in bronchial asthma
The recent development of new β2-adrenoceptor agonists with a duration of action in excess
of 12 h may change strategies in the treatment of bronchial asthma. This study aims at the …
of 12 h may change strategies in the treatment of bronchial asthma. This study aims at the …
Pharmacology of long-acting beta-agonists.
M Johnson - Annals of Allergy, Asthma & Immunology: Official …, 1995 - europepmc.org
Background When first developed more than 30 years ago, beta-agonists (eg, isoproterenol)
did not discriminate between beta 1-and beta 2-subtypes of the beta-adrenoceptor, resulting …
did not discriminate between beta 1-and beta 2-subtypes of the beta-adrenoceptor, resulting …
[HTML][HTML] Past, present and future—β2-adrenoceptor agonists in asthma management
The β-adrenoceptor agonists (β-agonists) have been used to relieve bronchoconstriction for
at least 5000 years. β-agonists are based on adrenaline and early forms, such as …
at least 5000 years. β-agonists are based on adrenaline and early forms, such as …
Clinical implications of the intrinsic efficacy of beta-adrenoceptor drugs in asthma: full, partial and inverse agonism
Rational choice among β 2-AR agonists in acute and chronic asthma should be influenced
by differences in intrinsic efficacy among these agents. In acute severe asthma, a full agonist …
by differences in intrinsic efficacy among these agents. In acute severe asthma, a full agonist …
β-Adrenoceptor agonists and asthma—100 years of development
B Waldeck - European journal of pharmacology, 2002 - Elsevier
Inhaled β2-adrenoceptor agonists are by far the most effective and safe bronchodilators
currently available. They have not been surpassed by any other bronchodilating principle …
currently available. They have not been surpassed by any other bronchodilating principle …